Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.

Compounds developed at Vanderbilt University may offer a new way to block influenza infection.

A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier.

Vanderbilt University’s Craig Lindsley, Ph.D., has won the 2014 John J. Abel Award in Pharmacology for young investigators from the American Society for Pharmacology and Experimental Therapeutics (ASPET).

Vanderbilt University researchers have discovered a “backdoor” approach to blocking an enzyme that fuels the growth of glioblastoma, the most common and most fatal form of brain cancer.